Location History:
- Khimki Moskovskoi oblasti, SU (1985)
- Moscow, SU (1987 - 1990)
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 1 Years Active: 1985-1990
Title: Innovations in Cardiac Treatment: The Contributions of Vladimir I Metelitsa
Introduction: Vladimir I Metelitsa, a prominent inventor based in Moscow, Russia, has made significant contributions to the field of medicine with his innovative inventions. With a total of four patents, his latest work particularly focuses on addressing ischemic heart disease.
Latest Patents: Metelitsa's most recent patent involves the development of an antianginal plate designed specifically for treating ischemic heart disease. This innovative antianginal composition comes in the form of a biologically soluble and resolvable film, which is introduced buccally on the gum or mouth mucosa for the rapid arrest and prevention of angina pectoris attacks. The film, measuring between 0.1 to 1.5 mm in thickness, utilizes a carrier that is predominantly formed from a homopolymer of acrylamide or vinylpyrrolidone, or a copolymer with acrylate. The formulation comprises 99 to 70 percent by weight of acrylamide with vinylpyrrolidone, along with 1 to 30 percent by weight of acrylate, providing an effective mechanism to deliver relief from cardiovascular distress.
Career Highlights: Throughout his career, Vladimir I Metelitsa has worked in esteemed institutions, most notably at the Vsesoyuny Kardiologichesky Nauchny Tsentr (All-Union Scientific Center of Cardiology). His extensive experience there has propelled his research and innovation in cardiac treatments.
Collaborations: Metelitsa has collaborated with notable coworkers in the field, including Eduard A Babaian and Anatoly B Davydov. These collaborations have undoubtedly contributed to the advancements in heart disease treatment and the development of cutting-edge medical technologies.
Conclusion: Vladimir I Metelitsa's innovative patents and his commitment to advancing cardiac health exemplify his significant role in the medical field. His work not only contributes to enhancing patient care but also reflects the essential nature of ongoing research and development in the treatment of ischemic heart disease.